Antibacterial Agents TRIZ Cases

New oral and injectable 9-aminomethyl tetracycline formulations improve bioavailability and stability to treat resistant bacterial infections.

Non-pyruvylated and partially pyruvylated Klebsiella O-antigen conjugates broaden subserotype coverage, including resistant strains.

Dual-target antibodies bind PcrV and Psl to reduce Pseudomonas load, inhibit biofilms, and stabilize lung function in bronchiectasis.

Specific E. coli strains establish gut colonization resistance to displace MDR Enterobacteriaceae without driving antibiotic resistance.

Modified pentamidine analogs target bacterial LPS to disrupt the Gram-negative outer membrane, boost antibiotic activity, and reduce toxicity.

Fear-inducing heterocyclic and isothiocyanate compounds activate TRPA1 to trigger hypothermia and anti-inflammatory protection.

By targeting the conserved ECF-ATP interface, these inhibitors block multiple vitamin uptake pathways and suppress resistant Gram-positive bacteria.

Fusion peptides raise MYC activity in target immune cells to boost leukocyte viability and immune response while limiting systemic side effects.

PorA epitope loops are inserted into an fHbp scaffold to preserve native conformation and broaden meningococcal vaccine coverage.

Structural changes to β-lactam side groups improve Gram-negative antibacterial activity while limiting drug resistance.

Thiol-reactive ADC linkers improve conjugation control, keep payloads stable in circulation, and release cytotoxic drugs more selectively in target cells.

A whey protein bio-complex adheres to oral surfaces and selectively kills pathogenic bacteria while preserving commensal flora in animals.

New triazoloquinazolinone derivatives inhibit S. aureus AgrA virulence signaling while retaining activity in human serum and albumin.

Near-infrared activated indocyanine green kills Gram-negative bacteria and mycoplasma without antibiotics, helping avoid drug resistance.

Protease- and pH-stable sdAbs bind C. difficile toxin B in the gut to block cytotoxicity, reduce recurrence, and preserve microbiome health.

Orthosomycin compounds delivered through the teat canal treat resistant mastitis pathogens in milk while limiting systemic absorption.

Filtered Croton lechleri latex targets MRSA, P. aeruginosa, and other skin pathogens while supporting healing and reducing inflammation.

A 12-epi pleuromutilin scaffold overcomes weak antiviral efficacy by blocking RNA virus entry and replication, including coronaviruses.

Small-molecule fascin inhibitors block tumor cell migration and invasion, adding a metastasis-focused treatment path beyond primary tumor growth control.

A C-9 modified minocycline composition treats or prevents resistant biodefense bacterial infections, including post-exposure use.

Selective control of STAT1 threonine 749 phosphorylation helps treat sepsis, colitis, and lupus without broadly blocking antiviral signaling.

Multi-coating oral capsules release oxygen in the intestinal lumen to suppress anaerobic bacteria without hyperbaric equipment.

Targeting the secreted LasB virulence factor weakens P. aeruginosa infections while avoiding membrane-penetration limits and reducing resistance pressure.

A modified monocyclic β-lactam compound targets resistant Gram-negative bacteria, including Pseudomonas aeruginosa, in pneumonia treatment.

A tryptophol acetate and tyrosol acetate composition disrupts quorum sensing to curb biofilms without driving antibiotic resistance.

Controlled light exposure and buffered formulation keep phthalocyanine dye conjugates stable, potent, and ready for targeted photoimmunotherapy.

A defined crystal form A improves stability and pharmacokinetic behavior of an FXR-modulating tricyclic compound for pharmaceutical use.

Heat-inactivated Mycobacterium bovis is used to induce broad protection against protozoan and bacterial infections while avoiding active mycobacterial harm.

Novel anti-TIM-3 antibodies use targeted hinge and glycosylation changes to improve binding affinity and neutralize TIM-3 activity.

Short HD-5 and HNP-4 peptide fragments target resistant pathogens while preserving gut microbiome balance and simplifying manufacture.

Using Leuconostoc and Lactobacillus in kimchi, this case shows food-based H. pylori inhibition without antibiotic resistance or gut flora disruption.

D-configured antimicrobial peptides improve stability and efficacy against MDR and XDR pathogens while reducing hemolytic activity.

Engineered HMGB1 derivatives sequester DNABII proteins to break biofilms, restore antimicrobial susceptibility, and avoid excess inflammation.

Histidine-based unnatural amino acids help peptides resist proteolysis, improve bacterial selectivity, and inhibit multi-resistant bacteria.

Cationic naphthoic acid polymers disrupt bacterial membranes to target MDR gram-negative bacteria while maintaining selectivity.

Quadruple-action topical compounds inhibit melanin, suppress acne bacteria, and reduce inflammation to treat acne vulgaris and PIH.

A hydrochloric acid-DMSO-water formulation improves porphyrin photosensitizer solubility while reducing toxicity and preserving carrier compatibility.

Crystalline tebipenem pivoxil salt forms improve therapeutic efficacy and regulatory compliance while preserving practical manufacturability.

A three-strain oral probiotic composition helps prevent recurrent urogenital infections while reducing inflammation and restoring vaginal pH.

PEGylated porcine G-CSF variants raise neutrophil counts to prevent MMA syndrome in periparturient sows without antibiotics.

Adding HVEM co-stimulation to CAR constructs boosts cytotoxicity, metabolic activity, and memory subsets while reducing CAR-T cell exhaustion.

Using the C-terminal NHBA fragment boosts bactericidal and opsonophagocytic antibodies against N. gonorrhoeae despite antigenic variation.

Dendritic cells pulsed with overlapping HPV peptides expand naïve donor T cells without live viruses, enabling off-the-shelf cell therapy.

Light-activated porfimer sodium gel targets biofilms and resistant bacteria, improving in vivo antimicrobial treatment of difficult infections.

A defined mix of lactic, butyric, and propionic acids rebalances gut microbiota by raising butyrate producers and lowering sulfide producers.

Inactivated L. crispatus cells with D-lactate help restore vaginal homeostasis without live probiotic safety and stability limits.

Novel tricyclic spirolactams target drug-tolerant M. tuberculosis to help shorten lengthy TB treatment and address resistant strains.

Co-lyophilizing durlobactam and sulbactam improves powder flow and stability, enabling consistent fixed dosing with less adhesion and waste.

Durlobactam with sulbactam treats resistant Acinetobacter pneumonia while lowering nephrotoxicity versus colistin in critically ill patients.

Novel lytic phage cocktails combine DH2, DH5, and DS10 to treat MDR Staphylococcus while reducing resistance risk across human and animal infections.

Pediococcus acidilactici and Bacillus amyloliquefaciens colonize hatcher cabinets, displacing pathogens without chemical disinfectant hazards.

Modified chlorotonil derivatives exhibit enhanced water solubility through semi-synthetic epoxide introduction.

Specific heterocyclic structures overcome bacterial antibiotic resistance by functioning as both antibacterial agents and beta-lactamase inhibitors.

A composite formulation of aliphatic alcohols and fatty acid esters targets nasal and wound sites to reduce bacterial loads.

Cloning the PmTLS gene produces a protease inhibitor that suppresses resistant pathogens like Pseudomonas aeruginosa without triggering antibiotic resistance.

High passage attenuated Mycoplasma bovis strains resolve manufacturing consistency and immune response trade-offs to reduce clinical symptoms.

VHH antibodies targeting Salmonella motility and adhesion proteins replace costly vaccines, reducing infection risk without antibiotic resistance.

Targeting melanosome maturation via IFN-γ signaling reduces melanin content and alters transfer, resolving side effects from disrupting cellular processes.

Fluorine-substituted peptidyl nitrile compounds inhibit dipeptidyl peptidase I to treat inflammatory diseases.

Bacteriocin-like inhibitory substances target Propionibacterium acnes to treat acne without triggering antibiotic resistance.

Amine-containing phenoxy alkyl diethanolamine compounds form non-covalent mixtures with active agents to facilitate transport across biological barriers.

Composite collagen VI peptides enhance antimicrobial activity while reducing cytotoxicity to treat resistant wound infections.

Antibody 13C4 targets the Stx1 epitope to neutralize cytotoxicity, enabling safe antibiotic use for hemolytic uremic syndrome.

HPTPβ inhibitors prevent vascular leak syndrome by stabilizing the endothelium, enabling effective interleukin-2 cancer therapy.

Imidazole and thiazole compounds resolve specificity contradictions by inhibiting LPS-induced IL-6 and iNOS for targeted therapeutic applications.

Ex vivo expansion of haematopoietic precursors using STRO-1 bright cells increases the available cell dose to resolve low engraftment rates in adult patients.

AdB-2/3 fiber multimers bind DSG2 receptors to trigger transient intercellular junction opening.

Substituted tricyclic acid derivatives act as selective S1P1 receptor agonists to modulate leukocyte trafficking and enhance vascular integrity.

A dermatological composition combines algae and olive leaf extracts to treat microbial infections.

Replacing phosphate buffers with amino acids reduces protein aggregation while maintaining pH stability and tolerability.